Cite
HARVARD Citation
Wainberg, Z. et al. (n.d.). 317 Safety and efficacy results from a phase 1 dose-escalation trial of the parp inhibitor talazoparib (bmn-673) in combination with either temozolomide or irinotecan in patients with advanced malignancies. European journal of cancer. pp. S60-. [Online].